Nasdaq, S&P Up On The Week, Dow Down

Stocks finished mixed on Friday, with blue-chips sinking after December jobs data trailed analyst forecasts but broader market gauges closed the session and the week with gains. Most industry sectors in the S&P 500 ended the day in the black, led by utility stocks. Shares of healthcare and consumer staple stocks also outperformed, reflecting investor caution Friday.

NFP Numbers
Non-farm payrolls increased by an anemic 74,000 in December, well below the consensus estimate expecting a 191,000 gain. November hiring was revised upward by 38,000 additional workers while the jobless rate fell to 6.7% - its lowest mark since October 2008.

Other data Friday included an as-expected 0.5% gain in November wholesale inventories.

Commodities
Crude oil for February delivery settled $1.06 lower at $92.72 per barrel while February natural gas finished with a 5-cent gain at $4.05 per 1 million BTU. February gold rose $17.30 to $1,246.60 per ounce while March silver added 55 cents to $20.23 per share. March copper climbed 4 cents to $3.34 per pound.

Here's Where The U.S. Markets Stood At Day's End

• Dow Jones Industrial Average down 7.71 (-0.05%) to 16437.05

• S&P 500 up 4.24 (0.23%) to 1842.37

• Nasdaq Composite Index up 18.47 (+0.44%) to 4174.66

• Hang Seng Index up 0.26%

• Shanghai China Composite Index down 0.71%

• FTSE 100 Index up 0.73%

• (+), ICPT Continues Thursday's rally triggered after its obeticholic adic study for the treatment of nonalcoholic steatohepatitis was stopped early after an interim analysis showed it already met the primary endpoint.

• (+) IMMU, Reported the first patient dosing in the company's Phase III registration study of its pancreatic cancer drug, yttrium-90 (90Y)-clivatuzumab tetraxetan.

• (+), ANF (+9.8%) Boosts its guidance for full-year adjusted earnings based on better-than-expected sales and cost cuts.

• (-) CHTP, FDA briefing document on Northera cites "lack of sufficient evidence of efficacy".

• (-) PSUN, Expects its Q4 non-GAAP loss per diluted share from continuing operations to be in the range of $0.21 - $0.18 versus estimates of a loss of $0.14 per share.

• (-) BV, Federal judge in San Francisco ruled in favor of the government in its anti-trust lawsuit challenging the company's acquisition of rival PowerReviews.